



LKT Laboratories, Inc.

Pelitinib

Phone: 888-558-5227

651-644-8424

Fax: 888-558-7329

Email: getinfo@lktlabs.com

Web: lktlabs.com

Product Information

Product ID P1845

CAS No. 257933-82-7

Chemical Name (E)-N-(4-((3-chloro-4-fluorophenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide

Synonym EKB-569

Formula C₂₄H₂₃ClFN₅O₂

Formula Wt. 467.92

Melting Point 188-190°C (lit.)


Purity ≥98%

Solubility Insoluble in water. Soluble in DMSO (≥13 mg/mL).

Store Temp Ambient

Ship Temp Ambient

Description Pelitinib is an irreversible EGFR inhibitor that exhibits anticancer chemotherapeutic benefit in the treatment of non-small cell lung cancer (NSCLC) and other solid tumor cancers. In vitro, pelitinib inhibits NF-κB, inhibiting transcription of TERT and telomerase activity. Pelitinib also decreases phosphorylation of Akt and ERK and induces cell cycle arrest in vitro.



Bulk quantities available upon request

Product ID	Size
P1845	1 mg
P1845	5 mg
P1845	10 mg
P1845	25 mg
P1845	100 mg

References Aravindan N, Aravindan S, Herman TS, et al. EGFR tyrosine kinase inhibitor pelitinib regulates radiation-induced p65-dependent telomerase activation in squamous cell carcinoma. *Radiat Res.* 2013 Mar;179(3):304-12. PMID: 23379415.

Kim H, Lim HY. Novel EGFR-TK inhibitor EKB-569 inhibits hepatocellular carcinoma cell proliferation by AKT and MAPK pathways. *J Korean Med Sci.* 2011 Dec;26(12):1563-8. PMID: 22147992.

Yoshimura N, Kudoh S, Kimura T, et al. EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. *Lung Cancer.* 2006 Mar;51(3):363-8. PMID: 16364494.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.